| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/08/2001 | US6228888 Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| 05/08/2001 | US6228880 Parkinson*s disease, tourette*s syndrome, schizophrenia, alcoholism, drug abuse; side effect reduction |
| 05/08/2001 | US6228875 Administering derivative of alanine or serine as agonist of nmda receptor; alzheimer*s disease, psychological and nervous system disorders, schizophrenia; cognition activators |
| 05/08/2001 | US6228872 Neurotrophic diamide and carbamate agents |
| 05/08/2001 | US6228863 Mixing orally active agonist and antagonist; two-step extraction required for separation; injection |
| 05/08/2001 | US6228859 Antiasthmatic, antiinflammatory, antiallergen and antidepressant agents |
| 05/08/2001 | US6228619 Glucosaminidase |
| 05/08/2001 | US6228398 Dosage form for increasing patient compliance by reducing dosage frequency; attention deficit disorder, methylphenidate or salts |
| 05/08/2001 | US6227195 Coarse spray delivery of functional biologic material |
| 05/08/2001 | CA2324484A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2324330A1 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same |
| 05/08/2001 | CA2323464A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323191A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323183A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2167040C New alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them |
| 05/08/2001 | CA2032141C Pharmaceutically active agents that impede amyloid formation in vivo |
| 05/08/2001 | CA2027530C W-phenoxy-heterocyclic compounds |
| 05/03/2001 | WO2001031054A1 Method of screening for inhibitors of asp1 |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031021A1 Multiple sclerosis-related superantigen |
| 05/03/2001 | WO2001031014A2 G protein-coupled receptors expressed in human brain |
| 05/03/2001 | WO2001031008A2 Human and rat fgf-20 genes and gene expression products |
| 05/03/2001 | WO2001031007A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | WO2001031005A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | WO2001030978A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | WO2001030972A2 Regulation of gene expression by neuroleptic agents |
| 05/03/2001 | WO2001030969A2 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | WO2001030845A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 05/03/2001 | WO2001030844A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | WO2001030777A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | WO2001030774A1 Substituted indoles for modulating nfkb activity |
| 05/03/2001 | WO2001030767A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030761A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 05/03/2001 | WO2001030734A1 Novel hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030350A1 Treating sleep disorders using desloratadine |
| 05/03/2001 | WO2001030349A1 Amorphous paroxetine compositon |
| 05/03/2001 | WO2001030346A1 Treatment of dyskinesia |
| 05/03/2001 | WO2001030345A1 Clonidine preparations |
| 05/03/2001 | WO2001030339A1 Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
| 05/03/2001 | WO2001030335A2 Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| 05/03/2001 | WO2001030332A2 Methods of protecting neuronal function |
| 05/03/2001 | WO2001030330A2 Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| 05/03/2001 | WO2001030328A2 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | WO2001030321A1 Oral dosage form comprising a salt of morphine or a morphine derivative |
| 05/03/2001 | WO2001030318A1 Oral solution containing galanthamine and a sweetening agent |
| 05/03/2001 | WO2001030287A1 Local prevention or amelioration of pain from surgically closed wounds |
| 05/03/2001 | WO2001030137A1 N-calcium channel knockout animal |
| 05/03/2001 | WO2001000221A3 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 05/03/2001 | WO2000077168A3 ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS |
| 05/03/2001 | WO2000074712A3 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 05/03/2001 | WO2000074695A3 Tanacetum parthenium extract |
| 05/03/2001 | WO2000072876A3 Prevention and treatment of amyloidogenic disease |
| 05/03/2001 | WO2000068263A3 Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| 05/03/2001 | WO2000066546A3 Monofluoroalkyl derivatives |
| 05/03/2001 | WO2000065028A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 05/03/2001 | DE19951970A1 Arzneimittel für die Toleranzinduktion Medicines for tolerance induction |
| 05/03/2001 | DE19951702A1 Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten Use of 2-amino-3,4-dihydro-quinazolines for the preparation of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions |
| 05/03/2001 | DE19951671A1 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist and its use as an endothelin antagonist |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | DE10038203A1 Implantable active agent depot, useful e.g. in local tumor treatment or gene therapy, comprising drug-containing, cubic phase forming lipid matrix containing modifier molecule to control release kinetics |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2389110A1 Regulation of gene expression by neuroleptic agents |
| 05/03/2001 | CA2389031A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | CA2389012A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | CA2388974A1 Medicament in order to induce tolerance |
| 05/03/2001 | CA2388965A1 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | CA2388637A1 Human fgf-20 gene and gene expression products |
| 05/03/2001 | CA2388617A1 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | CA2388611A1 Transdermal drug delivery devices |
| 05/03/2001 | CA2388599A1 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | CA2388123A1 Oral dosage form comprising a salt of morphine or a morphine derivative |
| 05/03/2001 | CA2388121A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | CA2388119A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | CA2387685A1 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | CA2387680A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 05/03/2001 | CA2387506A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | CA2386908A1 Treating sleep disorders using desloratadine |
| 05/03/2001 | CA2386509A1 G protein-coupled receptors expressed in human brain |
| 05/03/2001 | CA2386441A1 Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| 05/03/2001 | CA2385929A1 Use of gdnf for treating corneal defects |
| 05/02/2001 | EP1096008A2 Human G protein-coupled receptor, PFI-014 |
| 05/02/2001 | EP1095941A1 Process and crystal forms of 2-methyl-thieno-benzodiazepine |
| 05/02/2001 | EP1095939A2 Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds |
| 05/02/2001 | EP1095656A2 Pharmaceutical preparation comprising Galanthamine as cholinesterase inhibitor |
| 05/02/2001 | EP1095655A2 NK-1 receptor antagonists and eletriptan for the treatment of migraine |
| 05/02/2001 | EP1095651A2 Multipor food protection |
| 05/02/2001 | EP1095279A1 Method for identifying a presenilinase inhibitor |
| 05/02/2001 | EP1095154A2 Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon) |
| 05/02/2001 | EP1095148A2 Cloning and characterisation of novel mammalian peptidases |
| 05/02/2001 | EP1095140A2 Neurotrophic factors |
| 05/02/2001 | EP1095136A1 Cells and animals deficient in protein kinase c epsilon |
| 05/02/2001 | EP1095057A1 Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof |
| 05/02/2001 | EP1095039A2 New pharmaceutically active compounds |
| 05/02/2001 | EP1095038A1 Antagonists of gonadotropin releasing hormone |
| 05/02/2001 | EP1095031A1 Antiviral macrocyclic compounds |